Longeveron said that intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo.
Longeveron Inc. (LGVN) reported Q2 2025 earnings with revenue missing estimates at $320K but a narrower EPS loss of $0.33. Stock fell 3.5% post-earnings amid clinical progress in HLHS and Alzheimer's trials.
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
